Abstract
A library with 63 paclitaxel analogues modified at the C10 position of paclitaxel has been prepared using parallel solution phase synthesis. Most of the C10 analogues were slightly less active than paclitaxel in the tubulin assembly assay and had reduced potency in the B16 melanoma and MCF-7 cell line cytotoxicity assays. These modifications at C10, however, did not lead to the total loss of activity, indicating that the C10 moiety of paclitaxel may not be directly involved in the drug-microtubule interactions, but could influence its binding affinity to P-glycoprotein. Approximately 50 percentof the analogues demonstrated better activity against the drug resistant cell line MCF7-ADR. However, the increase in activity was 10-fold at most. This result demonstrates that the cytotoxicity against this drug resistant cancer cell line is sensitive to structural changes at the C10 position of paclitaxel. It was also found that the presence of a nitrogen atom in the C10 substituent might play a role in the i nteraction of analogues with microtubules.
Keywords: Paclitaxel Analogues, taxus brevifolia, alzheimer disease, combinatorial chemistry, taxanes, tubulin assembly assay, cell cytotoxicity assay
Combinatorial Chemistry & High Throughput Screening
Title: A Systematic SAR Study of C10 Modified Paclitaxel Analogues Using a Combinatorial Approach
Volume: 5 Issue: 1
Author(s): Yanbin Liu, Syed M. Ali, Thomas C. Boge, Gunda I. Georg, Samuel Victory, Jan Zygmunt, Rebecca T. Marquez and Richard H. Himes
Affiliation:
Keywords: Paclitaxel Analogues, taxus brevifolia, alzheimer disease, combinatorial chemistry, taxanes, tubulin assembly assay, cell cytotoxicity assay
Abstract: A library with 63 paclitaxel analogues modified at the C10 position of paclitaxel has been prepared using parallel solution phase synthesis. Most of the C10 analogues were slightly less active than paclitaxel in the tubulin assembly assay and had reduced potency in the B16 melanoma and MCF-7 cell line cytotoxicity assays. These modifications at C10, however, did not lead to the total loss of activity, indicating that the C10 moiety of paclitaxel may not be directly involved in the drug-microtubule interactions, but could influence its binding affinity to P-glycoprotein. Approximately 50 percentof the analogues demonstrated better activity against the drug resistant cell line MCF7-ADR. However, the increase in activity was 10-fold at most. This result demonstrates that the cytotoxicity against this drug resistant cancer cell line is sensitive to structural changes at the C10 position of paclitaxel. It was also found that the presence of a nitrogen atom in the C10 substituent might play a role in the i nteraction of analogues with microtubules.
Export Options
About this article
Cite this article as:
Liu Yanbin, Ali M. Syed, Boge C. Thomas, Georg I. Gunda, Victory Samuel, Zygmunt Jan, Marquez T. Rebecca and Himes H. Richard, A Systematic SAR Study of C10 Modified Paclitaxel Analogues Using a Combinatorial Approach, Combinatorial Chemistry & High Throughput Screening 2002; 5 (1) . https://dx.doi.org/10.2174/1386207023330615
DOI https://dx.doi.org/10.2174/1386207023330615 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Role for SNX1 in the Regulation of EGF-Dependent Phosphorylated EGFR Endocytosis Via the Early/Late Endocytic Pathway in a Gefitinib-Sensitive Human Lung Cancer Cells
Current Signal Transduction Therapy Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy
Current Drug Targets Inhibition of Angiogenesis by Cleaved High Molecular Weight Kininogen (HKa) and HKa Domain 5
Current Cancer Drug Targets Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Delivery of Curcumin and Medicinal Effects of the Copper(II)-Curcumin Complexes
Current Pharmaceutical Design Role of Stem Cells in Normal Liver and Cancer
Anti-Cancer Agents in Medicinal Chemistry Homocysteine-Lowering Treatment in Coronary Heart Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases
Current Pharmaceutical Design Polyphenol Supplementation as a Complementary Medicinal Approach to Treating Inflammatory Bowel Disease
Current Medicinal Chemistry The Therapeutic Potential of 4-1BB (CD137) in Cancer
Current Cancer Drug Targets ATRA Entrapped in DSPC Liposome Enhances Anti-metastasis Effect on Lung and Liver During B16F10 Cell Line Metastasis in C57BL6 Mice
Anti-Cancer Agents in Medicinal Chemistry Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer
Current Molecular Medicine A State-of-the-art Review and Prospective Therapeutic Applications of Prenyl Flavonoids as Chemosensitizers against Antifungal Multidrug Resistance in <i>Candida albicans</i>
Current Medicinal Chemistry (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Cucurbitacin B Induces DNA Damage, G2/M Phase Arrest, and Apoptosis Mediated by Reactive Oxygen Species (ROS) in Leukemia K562 Cells
Anti-Cancer Agents in Medicinal Chemistry EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Oxidation Inhibits Iron-Induced Blood Coagulation
Current Drug Targets Applications of Circadian Metabolomics
Current Metabolomics Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued)